The quality of evidence supporting peptide research claims varies enormously across the published literature. At one extreme, randomized controlled trials with validated surrogate endpoints and rigorous blinding; at the other, uncontrolled rodent studies using commercially-sourced peptides with no CoA, no lot documentation, and dose selection based on weight rather than molar equivalents. Researchers and clinicians interpreting this literature require a structured framework for evidence quality assessment — one that accounts for the specific methodological vulnerabilities of preclinical peptide research.
Evidence Hierarchy for Peptide Research: Adapting Standard Frameworks
Standard evidence hierarchies (Oxford CEBM, GRADE) rank randomized controlled trials above observational studies above preclinical data. For research peptides, this hierarchy requires modification: Phase 2/3 RCT data exist only for GLP-1R/GIP-R agonists (Tirzepatide, Retatrutide) and a small number of peptide hormones with approved indications. The vast majority of research peptides — BPC-157, TB-500, GHK-Cu, Selank, Semax, DSIP, Epitalon — have their evidence base in rodent in vivo models, in vitro cell culture, and (for several Russian neuropeptides) Phase 2 trials outside ICH-harmonized regulatory frameworks. When appraising this literature, the relevant question is not simply "is there evidence?" but "is this evidence generalizable to the claimed mechanism, and was the compound quality documented?"
Critical Appraisal Checklist: Five Required Elements for Peptide Studies
A structured appraisal of any peptide research publication should verify:
- Compound documentation: Is the peptide identified by sequence, manufacturer, lot number, and purity? Studies using uncharacterized commercial peptides (no CoA) cannot confirm that observed effects are attributable to the stated compound.
- Dose specification in molar terms: mg/kg dosing without molecular weight normalization prevents cross-study comparison. Effective molar concentrations must be calculable from published data.
- Control group adequacy: Vehicle controls must match the peptide vehicle (buffer, DMSO concentration, osmolality). Unmatched vehicles introduce confounding, particularly in neurological endpoints where DMSO has independent CNS effects.
- Endpoint validation: Are assays validated for the species and tissue type used? Antibody cross-reactivity in murine ELISAs for human-sequence peptides requires explicit confirmation.
- Statistical rigor: Were multiple comparison corrections applied (Bonferroni, FDR)? Was power calculation pre-specified? Single-study positive results without replication require cautious interpretation regardless of p-value.
Common Biases in Peptide Preclinical Literature
Systematic review analyses of peptide preclinical literature identify recurring methodological issues: (1) Publication bias — negative results consistently underreported; (2) Dose extrapolation — effective murine doses frequently 10–50× higher on a mg/kg basis than any clinically relevant exposure, questioning translational relevance; (3) Acute vs. chronic exposure conflation — single-dose studies interpreted as supporting chronic-administration conclusions; (4) Outcome heterogeneity — different laboratories measuring nominally identical endpoints ("inflammation") with non-standardized assays prevents quantitative meta-analysis; (5) Compound substitution risk — studies using commercially sourced peptides without lot-level QC may have inadvertently studied degradation products or sequence variants.
Interpreting CoA Data as Part of Evidence Assessment
When a research publication references a commercial peptide supplier, the CoA documentation (or its absence) is a confound that reviewers must address explicitly. A CoA that includes only HPLC purity without MS identity confirmation cannot verify sequence. A CoA without endotoxin testing (LAL assay) means that any observed inflammatory endpoint may reflect LPS contamination rather than peptide pharmacology. Researchers should request and archive CoA documents for all peptides used in their studies, and should report these data in their methods sections — a practice currently rare but increasingly expected by higher-impact journals.
Evidence Standards and Research Use Classification
The evidence quality framework described applies to compounds used in research contexts. None of the research peptides discussed — BPC-157, TB-500, GHK-Cu, Selank, DSIP, Epitalon — have completed Phase 3 trials that would support therapeutic claims in any FDA or EMA-regulated indication. These compounds are for research and laboratory use only. Not for unsupervised human consumption.